Eli Lilly deal signals growing investment in psychedelic mental health drugs

Traders Union
All News
Financial News
Eli Lilly psychedelic drug deal

Highlights

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion, signaling large pharma's increased investment in psychedelic mental health therapies after positive clinical results and regulatory momentum.
AtaiBeckley's BPL-003, a synthetic 5-MeO-DMT nasal spray for treatment-resistant depression, shows rapid and durable symptom reductions, holds FDA Breakthrough Therapy Designation, and is now in Phase 3 trials.
Mordor Intelligence forecasts the psychedelic drugs market will grow from $4.08 billion in 2025 to $8.75 billion by 2031, with new launches from Compass Pathways and ongoing acquisitions by Otsuka and AbbVie.

Acquisition underscores regulatory and clinical momentum

As first reported by CNBC, Eli Lilly’s agreement to acquire clinical-stage psychedelic drug developer AtaiBeckley for up to $3.8 billion highlights how large pharmaceutical groups are moving deeper into a category long seen as controversial. The deal follows positive trial readouts across several psychedelic compounds and comes after President Trump’s April executive order to fast-track Food and Drug Administration reviews of such drugs.

AtaiBeckley’s lead candidate, BPL-003, is a synthetic 5-MeO-DMT nasal spray for treatment-resistant depression, a severe form of depression that does not improve after standard therapies and affects about four million Americans. The company reported Phase 2b data a year ago showing rapid and durable reductions in symptoms, and the drug now holds FDA Breakthrough Therapy Designation and is in Phase 3 testing.

Jefferies analysts say Phase 3 success by early 2029 could create a $1 billion to $2 billion opportunity in treatment-resistant depression. They also say key opinion leaders see psychedelics as a potentially major shift in psychiatry, with demand from patients already appearing very strong.

The broader field includes LSD, psilocybin, MDMA, ayahuasca and ibogaine, which companies are testing for depression, PTSD, anxiety, eating disorders and substance addiction. Researchers and analysts say these drugs can temporarily loosen entrenched patterns of brain communication, potentially helping patients revisit trauma, depression or addiction from a different perspective when paired with therapy.

Needham biotech analyst Ami Fadia says data generated so far suggests the class may offer more meaningful outcomes than widely used oral drugs such as SSRIs and SNRIs. She also says investor resistance has faded markedly compared with a few years ago.

Commercial hurdles and wider industry impact

The sector still faces regulatory and commercial obstacles despite stronger momentum. In August 2024, the FDA denied approval for Lykos Therapeutics’ MDMA-assisted PTSD therapy, a setback that showed how difficult it remains to bring Schedule I substances into mainstream medicine.

Even so, more recent trial results continue to support the field. Definium Therapeutics says its LSD-based drug DT120 posts positive Phase 3 data in major depressive disorder, and the company expects that, if additional anxiety studies are similarly strong, it can file a New Drug Application with the FDA within six to nine months. Because LSD remains a Schedule I substance, the drug would also require reclassification by the Drug Enforcement Administration and by individual states.

Insurance coverage is another key issue, since companies need coding and payer negotiations to secure reimbursement. Fadia points to Johnson & Johnson’s Spravato, a ketamine-derived nasal spray for difficult-to-treat depression, as proof that the model can work after substantial commercial and reimbursement effort; J&J reports last week that Spravato sales rise 40% year over year to $584 million.

Other large drugmakers are also expanding in the space. Japan’s Otsuka Pharmaceuticals acquires Transcend for $1.2 billion in June, while AbbVie bought Gilgamesh Pharmaceuticals’ next-generation psychedelic compound last year for $1.2 billion.

Mordor Intelligence values the psychedelic drugs market at $4.08 billion in 2025 and estimates it grows to $4.63 billion in 2026 and reaches $8.75 billion by 2031. Compass Pathways, another developer in the field, says its synthetic psilocybin drug COMP360 delivers strong Phase 3 results in treatment-resistant depression and that the company expects to be commercially ready by the end of this year, with a potential market launch in the first part of 2027.

Our earlier roundup of the week’s biggest venture funding deals showed capital concentrating in AI and adjacent technologies, led by Fireworks AI’s $1.505 billion Series D and other large rounds spanning delivery, robotics, drones, and infrastructure. The piece also pointed to sustained investor appetite for high-capital, sector-defining platforms and their industry-specific applications, despite broader market concerns about froth and potential overcapacity in parts of the AI buildout.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.